FDA NDA · NDA021971

LAMIVUDINE; ZIDOVUDINE; NEVIRAPINE

Sponsor: CIPLA LIMITED

APPLICATION

NDA021971

TYPE

NDA

ROUTE

ORAL

DOSAGE FORM

TABLET

MARKETING STATUS

None (Tentative Approval)

Products

LAMIVUDINE; ZIDOVUDINE; NEVIRAPINENone (Tentative Approval)

LAMIVUDINE 150MG, ZIDOVUDINE 300MG, NEVIRAPINE 200MG · TABLET · ORAL

2007-01-31Type 4 - New Combination · Original · priority — Letter ↗TA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.